# A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

> **NCT03586830** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 196 (actual)

## Conditions studied

- Obesity and Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** JNJ-64565111 Dose Level 1
- **DRUG:** JNJ-64565111 Dose Level 2
- **DRUG:** JNJ-64565111 Dose Level 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03586830
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-26
- **Primary completion:** 2019-04-05
- **Final completion:** 2019-04-05
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03586830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03586830, "A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03586830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*